As we look toward 2035, the Fibrodysplasia Ossificans Progressiva Market is projected to reach USD 2.80 billion, growing at a CAGR of 16.76%. The future of the market will be shaped by three key trends: the continued development of gene therapy, the identification and validation of biomarkers for patient stratification and monitoring, and the increasing emphasis on patient-centric care models.

Gene therapy represents the ultimate frontier for FOP treatment. By correcting the underlying ACVR1 gene mutation, gene therapy offers the potential for a one-time, durable cure. Several academic and industry groups are exploring gene therapy approaches, including adeno-associated virus (AAV) vectors and CRISPR-Cas9 gene editing. While these approaches are still in early stages of development, the rapid advances in gene therapy technology and the success of gene therapy for other rare diseases suggest that it could become a reality for FOP within the forecast period. If successful, gene therapy would not only transform the FOP market but would also serve as a model for other ultra-rare genetic disorders.

The identification and validation of biomarkers will be critical for patient stratification, monitoring disease progression, and assessing treatment response. Currently, the primary endpoint for FOP clinical trials is the reduction in new heterotopic ossification measured by whole-body CT. However, CT scans are not ideal for frequent monitoring due to radiation exposure. The development of non-invasive biomarkers, such as serum proteins or imaging biomarkers using [18F]NaF PET-CT, could enable more frequent and sensitive assessment of disease activity. The Phase 2 study of fidrisertib (IPN60130) is already using [18F]NaF PET-CT to evaluate HO lesions, reflecting the growing interest in advanced imaging biomarkers. Validated biomarkers would also facilitate the development of personalized treatment strategies, ensuring that patients receive the most appropriate therapy based on their individual disease profile.

The increasing emphasis on patient-centric care will be a defining trend. FOP is a devastating disease that profoundly impacts patients' quality of life. Future treatment paradigms will focus not only on reducing heterotopic ossification but also on managing pain, preserving mobility, and addressing the psychosocial aspects of the disease. This will require a multidisciplinary approach involving physicians, physical therapists, occupational therapists, and mental health professionals. Patient advocacy groups will continue to play a vital role in shaping research priorities and ensuring that patient voices are heard. The development of patient-reported outcome measures (PROMs) will be essential for capturing the impact of treatments on patients' daily lives.

Finally, the focus on global access will be a key challenge. Ultra-rare disease therapies are often extremely expensive, limiting access for patients in low- and middle-income countries. Innovative pricing models, patient assistance programs, and global health initiatives will be needed to ensure that all patients with FOP can benefit from new therapies. By 2035, the FOP market will be characterized by a diverse portfolio of targeted therapies, including potentially curative gene therapy, validated biomarkers for personalized treatment, and a strong emphasis on patient-centric, holistic care. The convergence of these trends will not only transform the lives of patients with FOP but will also serve as a blueprint for drug development and patient care for other ultra-rare diseases.